- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01092858
NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)
November 3, 2014 updated by: Bayer
Effect of Exercise Alone or in Combination With Testosterone Replacement on Muscle Strength and Quality of Life in Older Men With Low Testosterone Concentrations: a Randomized Double-blind, Placebo Controlled Study
The design of the study is a standard double-blind design, which is needed in this study to allow for unbiased evaluation of efficacy and safety.
The effect of the additional impact of testosterone replacement therapy in hypogonadal men on muscle strength and quality of life in comparison to physical exercise alone will be assessed.
Treatment duration will be 54 weeks, to monitor the increase as well as the "steady state" of the parameters assessed.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
4
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Nordrhein-Westfalen
-
Köln, Nordrhein-Westfalen, Germany, 50931
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
60 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Men aged 60 years and older (>60yrs), untrained
- Symptomatic hypogonadism as defined by a) and b)
- a) Total testosterone below 12 nmol/l (measurement 7.00-11.00 a.m.)
- b)Total Aging Males' symptom score above 36
- Willing to avoid significant change in the pattern of physical exercise and lifestyle for the duration of the study
- Residence in Cologne Area
Exclusion Criteria:
- Previous assignment to treatment during this study
- Use of androgen therapy or anabolic steroids respectively 12 months of entry into the study (i.e. screening visit/visit 1)
- Current participation in an exercise program or within the last 6 months
- Suspicion or known history of prostate or breast cancer or other hormone dependent neoplasia
- Abnormal finding on Digital Rectal Examination (DRE)
- Prostate specific antigen (PSA) level >4 ng/ml
- History of clinically significant post void residual urine (> 150 ml)
- Suspicion or known history of liver tumor
- Hypersensitivity to the active substances or any of the excipients of NEBIDO e.g. benzyl-benzoate and castor oil
- Blood coagulation irregularities presenting an increased risk of bleeding after intramuscular injections including vitamin-K-antagonists or other strong anticoagulants
- 32 Additional Exclusion Criteria
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
|
Testosterone undecanoate 1000 mg (4 ml) i.m. injection at baseline, at week 6, at week 18, at week 30 and at week 42, respectively
|
Placebo Comparator: Arm 2
|
Matching placebo i.m. injections at baseline, at week 6, at week 18 at week 30 and at week 42, respectively
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dynamic maximum strength -one repetition maximum (1-RM ) - of upper and lower extremity after 54 weeks
Time Frame: At baseline, at week 54
|
At baseline, at week 54
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Isometric maximum strength
Time Frame: At baseline, at week 54
|
At baseline, at week 54
|
Grip strength
Time Frame: At baseline, at week 54
|
At baseline, at week 54
|
Chair raising test
Time Frame: At baseline, at week 54
|
At baseline, at week 54
|
Arm curl test
Time Frame: At baseline, at week 54
|
At baseline, at week 54
|
Bicycle stress test with spirometry
Time Frame: At baseline, at week 54
|
At baseline, at week 54
|
SF-36 Questionnaire
Time Frame: At baseline, at week 54
|
At baseline, at week 54
|
AMS-Questionnaire
Time Frame: At baseline, at week 54
|
At baseline, at week 54
|
FINGER Questionnaire
Time Frame: At baseline, at week 54
|
At baseline, at week 54
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2010
Primary Completion (Actual)
July 1, 2011
Study Completion (Actual)
July 1, 2011
Study Registration Dates
First Submitted
March 24, 2010
First Submitted That Met QC Criteria
March 24, 2010
First Posted (Estimate)
March 25, 2010
Study Record Updates
Last Update Posted (Estimate)
November 5, 2014
Last Update Submitted That Met QC Criteria
November 3, 2014
Last Verified
November 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Gonadal Disorders
- Hypogonadism
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Androgens
- Anabolic Agents
- Testosterone
- Methyltestosterone
- Testosterone undecanoate
- Testosterone enanthate
- Testosterone 17 beta-cypionate
Other Study ID Numbers
- 14853
- 2009-017139-16 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypogonadism
-
Rigshospitalet, DenmarkTerminatedHypogonadotropic Hypogonadism | Hypogonadism | Hypogonadism, MaleDenmark
-
Shanghai Jiao Tong University School of MedicineUnknownIdiopathic Hypogonadotropic Hypogonadism
-
Endo PharmaceuticalsCompletedHypogonadotropic Hypogonadism | Hypogonadism | Hypogonadism, MaleUnited States
-
Clarus Therapeutics, Inc.CompletedMale Hypogonadism | Secondary Hypogonadism | Primary HypogonadismUnited States
-
Amneal Pharmaceuticals, LLCPhase One Solutions, Inc.CompletedHypogonadotropic Hypogonadism | Primary HypogonadismUnited States
-
Endo PharmaceuticalsCompletedHypogonadism | Secondary Hypogonadism | Primary HypogonadismUnited States
-
Repros Therapeutics Inc.CompletedObesity | Acquired Hypogonadotropic HypogonadismUnited States
-
Massachusetts General HospitalRecruiting
-
Mereo BioPharmaCompleted
-
Organon and CoCompleted
Clinical Trials on Testosterone Undeconate (Nebido, BAY86-5037)
-
BayerCompletedOsteoporosis | Hypogonadism | Paraplegia | Bone DensityGermany
-
BayerCompleted
-
BayerCompletedHypogonadism | MaleGermany, Indonesia, Korea, Republic of, Malaysia, Saudi Arabia, Singapore, Spain, Thailand, Philippines, Taiwan, Australia, Austria, Bulgaria, Colombia, Czech Republic, Estonia, Hong Kong, Italy, Jordan, Kazakhstan, Latvia, Lebanon, Lithuani... and more
-
Alexandra Kautzky-WillerBayerRecruitingFatty Liver | Hypogonadism, Male | Overweight/Obesity | Prediabetes/Type2 Diabetes MellitusAustria
-
University of Sao Paulo General HospitalCompleted
-
University Medical Centre LjubljanaCompletedObesity | Diabetes Mellitus, Type 2 | Hypogonadism, Male
-
Russian Academy of Medical SciencesUnknownMetabolic Syndrome | HypogonadismRussian Federation
-
Meir Medical CenterUnknown
-
Sheffield Teaching Hospitals NHS Foundation TrustBayerCompletedHypogonadism | Nonalcoholic SteatohepatitisUnited Kingdom